Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 12.35 · gapped above the open, then crossed back over prior close. High/low 12.84 at 6:45 am ET, 12.00 at 10:45 am ET.
Oric Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We previously entered into an ATM sales agreement with Jefferies LLC as our sales agent, to sell shares of our common stock.”
FILING10-K0001193125-26-064005cik 0001796280
“In January 2025, we announced that we entered into a clinical trial and supply agreement with Johnson & Johnson to evaluate enozertinib in combination with SC amivantamab for the first line treatment of patients with advanced NSCLC with EGFR exon 20 mutations, and we initiated a Phase 1b trial in the first quarter of 2025.”
FILING10-K0001193125-26-064005cik 0001796280
“We also announced that we entered into clinical trial collaboration and supply agreements with Johnson & Johnson and Bayer, to evaluate rinzimetostat in combination with Erleada ® (apalutamide), Johnson & Johnson's AR inhibitor, and Nubeqa ® (darolutamide), Bayer's AR inhibitor.”
FILING10-K0001193125-26-064005cik 0001796280
“Rinzimetostat (formerly ORIC-944), an allosteric inhibitor of the PRC2 via the EED subunit, for which we licensed development and commercialization rights from Mirati with the Mirati License Agreement.”
FILING10-K0001193125-26-064005cik 0001796280
“Under the Mirati License Agreement, Mirati granted us a worldwide, exclusive, sublicensable, royalty-free license under Mirati's rights to certain patents and patent applications directed to certain small molecule compounds that bind to and inhibit PRC2 and certain related know-how, in each case, to develop and commercialize certain licensed compounds and licensed products incorporating any such compound.”
FILING10-K0001193125-26-064005cik 0001796280
“Enozertinib (formerly ORIC-114), a brain-penetrant, orally bioavailable, irreversible inhibitor targeting EGFR exon 20 and EGFR atypical mutations, for which we licensed development and commercialization rights from Voronoi with the Voronoi License Agreement.”
FILING10-K0001193125-26-064005cik 0001796280
Watchlist prices, news filtered to it, and its next report on your desk.
Oric Pharmaceuticals, Inc. has 6 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Oric Pharmaceuticals, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Oric Pharmaceuticals, Inc.. Customers appear here when Oric Pharmaceuticals, Inc. names them, or when a company names Oric Pharmaceuticals, Inc. as a supplier in its own annual report.
ORIC (Oric Pharmaceuticals, Inc.) has 6 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: JEF −2.47%, in financials.